DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 Listed Suppliers

1 API Suppliers
1 Listed Suppliers

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: N-[2-[4-[n-(hexyloxycarbonyl)amidino]phenylaminomethyl]-1-methyl-1h-benzimidazol-5-ylcarbonyl]-n-(2-pyridyl)-beta-alanine ethyl ester, Rabigatran etexilate, Bibr1048, Bcpp000269, Bibr-1048 - dabigatran etexilate, Akos015900928

Molecular Formula

C₃₄H₄₁N₇O₅

Molecular Weight

627.7 g/mol

InChI Key

KSGXQBZTULBEEQ-UHFFFAOYSA-N

1 2D Structure

Pradax

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate

2.1.2 InChI

InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)

2.1.3 InChI Key

KSGXQBZTULBEEQ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CCCCCCOC(=O)N=C(C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)N

2.1.5 Isomeric SMILES

CCCCCCOC(=O)/N=C(/C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)\N

2.2 Synonyms

2.2.1 Depositor-Supplied Synonyms

1. N-[2-[4-[n-(hexyloxycarbonyl)amidino]phenylaminomethyl]-1-methyl-1h-benzimidazol-5-ylcarbonyl]-n-(2-pyridyl)-beta-alanine Ethyl Ester

2. Rabigatran Etexilate

3. Bibr1048

4. Bcpp000269

5. Bibr-1048 - Dabigatran Etexilate

6. Akos015900928

7. Am81239

8. Bcp9000578

9. Bs-1001

10. Ncgc00390544-02

11. Ab01563294_01

12. 915b069

13. Q-102504

14. Hexyl2-(4-(((5-((3-ethoxy-3-oxopropyl)(pyridin-2-yl)carbamoyl)-1-methyl-1h-benzo[d]imidazol-2-yl)methyl)amino)benzylidene)hydrazinecarboxylate

2.3 Create Date

2006-04-28

3 Chemical and Physical Properties

Molecular Formula	C₃₄H₄₁N₇O₅
Molecular Weight	627.7 g/mol
XLogP3	5.7
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	17
Exact Mass	627.31691743 g/mol
Monoisotopic Mass	627.31691743 g/mol
Topological Polar Surface Area	154 Å²
Heavy Atom Count	46
Formal Charge	0
Complexity	1000
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	1
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 1
Drug Name	PRADAXA
Active Ingredient	DABIGATRAN ETEXILATE MESYLATE
Company	BOEHRINGER INGELHEIM (Application Number: N022512. Patents: 6087380, 7866474, 7932273, 9034822)